Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism

Fig. 2

In vitro assessment of the liver targeting and intestinal barrier penetration ability of NCG. A Examination of NAR and NCG uptake by different cells, scar bar: 20 μm; B evaluation of the impact of ASGPR on NCG liver targeting, scar bar: 20 μm; C evaluation of NAR and NCG uptake in WRL-68 cells at 30 min and assessment of NAR and NCG uptake in WRL-68 cells at 10 min, 30 min, and 60 min, scar bar: 20 μm; D assessment of the capability of NAR and NCG penetrating the Caco-2 cell layer and the quantity absorbed by WRL-68 cells in the lower chamber, scar bar: 50 μm; E Zebrafish organ pattern diagram, and the uptake and distribution of NAR, NAR NPs, and NCG uptake by zebrafish; the green fluorescence indicates NAR

Back to article page